Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
1. Hydrogel capsules encapsulating cells, wherein the capsules consist of three layers: a first inner acellular core sufficient to maintain cell viability after implantation and wherein said core comprises a therapeutic, prophylactic, or diagnostic agent; a second hydrogel layer containing cells to be transplanted and selected from the group consisting of mammalian secretory, metabolic and structural cells and aggregates thereof; a third acellular barrier layer, wherein the permeability of said layer limits entry of immune cells, antibodies and cytokines; and
wherein the capsules have a mean diameter of greater than 1 mm and less than 8 mm and a have a reduced fibrotic reaction after implantation than capsules with the same cells and having a diameter of less than 1 mm; and
wherein the encapsulated cells secrete a therapeutically effective amount of a therapeutically effective substance to treat a disease for at least 30 days.
2. The hydrogel capsules of claim 1 , comprising a therapeutic agent selected from the group consisting of anti-inflammatories, phenolic antioxidants, and anti-proliferative drugs.
3. The hydrogel capsules of claim 1 , wherein the core comprises a therapeutic agent, which is released at the site of implantation.
4. The hydrogel capsules of claim 1 , wherein the cells are islet cells, or undifferentiated, or partially differentiated precursors thereof.
5. The hydrogel capsules of claim 1 , wherein the hydrogel layer comprises a polymer selected from the group consisting of polysaccharides, collagen, agarose, polyphosphazenes, poly(acrylic acids), poly(methacrylic acids), copolymers of acrylic acid and methacrylic acid, poly(alkylene oxides), poly(vinyl acetate), polyvinylpyrrolidone, and copolymers and blends thereof.
6. The hydrogel capsules of claim 5 , wherein the hydrogel layer comprises a polysaccharide selected from the group consisting of alginate, chitosan, hyaluronan, and chondroitin sulfate.
7. The hydrogel capsules of claim 1 , wherein the mammalian cells are allogeneic or autologous.
8. The hydrogel capsules of claim 1 , wherein the mammalian cells are islet cells.
9. Hydrogel capsules encapsulating cells, wherein the capsules consist of two or more layers: a hydrogel layer containing cells to be transplanted and selected from the group consisting of mammalian secretory, metabolic and structural cells and aggregates thereof; an outer acellular barrier layer, wherein the permeability of said layer limits entry of immune cells, antibodies and cytokines; and
wherein the capsules have a mean diameter of greater than 1 mm and less than 8 mm and have a reduced fibrotic reaction after implantation than capsules with the same cells and having a diameter of less than 1 mm; and
wherein the encapsulated cells secrete a therapeutically effective amount of a therapeutically effective substance to treat a disease for at least 30 days.
10. The hydrogel capsules of claim 9 , having a diameter of at least 1.2 mm.
11. The hydrogel capsules of claim 9 , having a diameter of at least 1.5 mm.
12. The hydrogel capsules of claim 9 , wherein the hydrogel layer comprises a polymer selected from the group consisting of polysaccharides, collagen, agarose, polyphosphazenes, poly(acrylic acids), poly(methacrylic acids), copolymers of acrylic acid and methacrylic acid, poly(alkylene oxides), poly(vinyl acetate), polyvinylpyrrolidone, and copolymers and blends thereof.
13. The hydrogel capsules of claim 12 , wherein the hydrogel layer comprises a polysaccharide selected from the group consisting of alginate, chitosan, hyaluronan, and chondroitin sulfate.
14. The hydrogel capsules of claim 12 , wherein the mammalian cells are islet cells.
15. The hydrogel capsules of claim 1 , wherein the encapsulated cells secrete a therapeutically effective amount of a therapeutically effective substance to treat a disease for at least 60 days.
16. The hydrogel capsules of claim 1 , wherein the encapsulated cells secrete a therapeutically effective amount of a therapeutically effective substance to treat a disease for at least 90 days.
17. The hydrogel capsules of claim 2 , wherein the anti-inflammatory drug is released from the capsules after administration to a mammalian subject.
18. The hydrogel capsules of claim 2 , wherein the anti-inflammatory drug provides spatially localized inhibition of inflammation in a subject in need thereof without systemic immunosuppression for at least 10 days.
19. The hydrogel capsules of claim 2 , wherein the anti-inflammatory drug provides spatially localized inhibition of inflammation in a subject in need thereof without systemic immunosuppression for at least 14 days.
20. The hydrogel capsules of claim 2 , wherein the anti-inflammatory drug provides spatially localized inhibition of inflammation in a subject in need thereof without systemic immunosuppression for at least 30 days.
21. The hydrogel capsules of claim 4 , wherein the islet cells, or undifferentiated, or partially differentiated precursors thereof secrete a therapeutically effective amount of insulin to treat diabetes in a subject for at least 30 days.
22. The hydrogel capsules of claim 4 , wherein the islet cells, or undifferentiated, or partially differentiated precursors thereof secrete a therapeutically effective amount of insulin to treat diabetes in a subject for at least 60 days.
23. The hydrogel capsules of claim 4 , wherein the islet cells, or undifferentiated, or partially differentiated precursors thereof secrete a therapeutically effective amount of insulin to treat diabetes in a subject for at least 90 days.